AMPD1 polymorphism and response to regadenoson

Pharmacogenomics. 2015 Nov;16(16):1807-15. doi: 10.2217/pgs.15.116. Epub 2015 Nov 10.

Abstract

Aims: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson.

Subjects & methods: Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing.

Results: Carriers of c.34C >T variant exhibited higher relative changes in systolic blood pressure (SBP) compared with wild-type subjects ([%] SBP change to peak: 12 ± 25 vs 5 ± 13%; p = 0.01) ([%] SBP change to nadir: -3 ± 15 vs -7 ± 11%; p = 0.04). Change in heart rate was similar between groups, but side effects were more common in carriers of the variant (+LR = 4.2; p = 0.04).

Conclusion: AMPD1 deficiency may be involved in the modulation of regadenoson's systemic effects.

Keywords: adenosine; genetic; myocardial perfusion imaging; regadenoson.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • AMP Deaminase / deficiency*
  • AMP Deaminase / genetics*
  • Adenosine A2 Receptor Agonists / pharmacology
  • Blood Pressure / drug effects
  • Blood Pressure / genetics*
  • Exercise Test / drug effects
  • Exercise Test / methods
  • Female
  • Heart Rate / drug effects
  • Heart Rate / genetics*
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic / genetics*
  • Purines / pharmacology*
  • Pyrazoles / pharmacology*

Substances

  • Adenosine A2 Receptor Agonists
  • Purines
  • Pyrazoles
  • regadenoson
  • AMP Deaminase
  • AMPD1 protein, human